A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern

References

• Beaudoin-Bussieres G, Laumaea A, Anand SP, et al. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio. 2020;11(5). doi:10.1128/mBio.02590-20.
   PubMed Web of Science ®Google Scholar
• Kustin T, Harel N, Finkel U, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021;27(8):1379–1384. doi:10.1038/s41591-021-01413-7
   PubMed Web of Science ®Google Scholar
• Becker M, Dulovic A, Junker D, et al. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nat Commun. 2021;12(1):3109. doi:10.1038/s41467-021-23473-6
   PubMed Web of Science ®Google Scholar
• Peng Q, Zhou R, Wang Y, et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. EBioMedicine. 2022;77:103904. doi:10.1016/j.ebiom.2022.103904
   PubMed Web of Science ®Google Scholar
• Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220. doi:10.1038/s41586-020-2180-5
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281–292 e6. doi:10.1016/j.cell.2020.02.058
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271–280 e8. doi:10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;183(6):1735. doi:10.1016/j.cell.2020.11.032
   PubMed Web of Science ®Google Scholar
• Duan L, Zheng Q, Zhang H, Niu Y, Lou Y, Wang H. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: implications for the Design of Spike-Based Vaccine Immunogens. Front Immunol. 2020;11:576622. doi:10.3389/fimmu.2020.576622
   PubMed Web of Science ®Google Scholar
• Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science. 2020;369(6504):650–655. doi:10.1126/science.abc6952
   PubMed Web of Science ®Google Scholar
• Wu Y, Li C, Xia S, et al. Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host Microbe. 2020;27(6):891–898 e5. doi:10.1016/j.chom.2020.04.023
   PubMed Web of Science ®Google Scholar
• Shi R, Shan C, Duan X, et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature. 2020;584(7819):120–124. doi:10.1038/s41586-020-2381-y
   PubMed Web of Science ®Google Scholar
• Wagner TR, Ostertag E, Kaiser PD, et al. NeutrobodyPlex-monitoring SARS-CoV-2 neutralizing immune responses using nanobodies. EMBO Rep. 2021;22(5):e52325. doi:10.15252/embr.202052325
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–797. doi:10.1146/annurev-biochem-063011-092449
   PubMed Web of Science ®Google Scholar
• Konwarh R. Nanobodies: prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2. Front Immunol. 2020;11:1531. doi:10.3389/fimmu.2020.01531
   PubMed Web of Science ®Google Scholar
• Haga K, Takai-Todaka R, Matsumura Y, et al. Nasal delivery of single-domain antibody improves symptoms of SARS-CoV-2 infection in an animal model. PLoS Pathog. 2021;17(10):e1009542. doi:10.1371/journal.ppat.1009542
   PubMed Web of Science ®Google Scholar
• Laursen NS, Friesen RHE, Zhu X, et al. Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin. Science. 2018;362(6414):598–602. doi:10.1126/science.aaq0620
   PubMed Web of Science ®Google Scholar
• Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020;41(5):355–359. doi:10.1016/j.it.2020.03.007
   PubMed Web of Science ®Google Scholar
• Li D, Sempowski GD, Saunders KO, Acharya P, Haynes BF. SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment. Annu Rev Med. 2022;73:1–16. doi:10.1146/annurev-med-042420-113838
   PubMed Web of Science ®Google Scholar
• Lee CM, Iorno N, Sierro F, Christ D. Selection of human antibody fragments by phage display. Nat Protoc. 2007;2(11):3001–3008. doi:10.1038/nprot.2007.448
   PubMed Web of Science ®Google Scholar
• Schoof M, Faust B, Saunders RA, et al. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. Science. 2020;370(6523):1473–1479. doi:10.1126/science.abe3255
   PubMed Web of Science ®Google Scholar
• Huo JD, Le Bas A, Ruza RR, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846–+. doi:10.1038/s41594-020-0469-6
   PubMed Web of Science ®Google Scholar
• Li Q, Zhang F, Lu Y, et al. Highly potent multivalent VHH antibodies against Chikungunya isolated from an alpaca naive phage display library. J Nanobiotechnology. 2022;20(1):231. doi:10.1186/s12951-022-01417-6
   PubMed Web of Science ®Google Scholar
• Cabanas-Danes J, Rodrigues ED, Landman E, et al. A supramolecular host-guest carrier system for growth factors employing V(H)H fragments. J Am Chem Soc. 2014;136(36):12675–12681. doi:10.1021/ja505695w
   PubMed Web of Science ®Google Scholar
• Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583–589. doi:10.1038/s41586-021-03819-2
   PubMed Web of Science ®Google Scholar
• Lee CV, Liang WC, Dennis MS, Eigenbrot C, Sidhu SS, Fuh G. High-affinity human antibodies from phage-displayed synthetic fab libraries with a single framework scaffold. J Mol Biol. 2004;340(5):1073–1093. doi:10.1016/j.jmb.2004.05.051
   PubMed Web of Science ®Google Scholar
• Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–687. doi:10.1038/s41586-020-2852-1
   PubMed Web of Science ®Google Scholar
• Huo J, Le Bas A, Ruza RR, et al. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Nat Struct Mol Biol. 2020;27(9):846–854. doi:10.1038/s41594-020-0469-6
   PubMed Web of Science ®Google Scholar
• Tang Q, Owens RJ, Naismith JH. Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2. Viruses. 2021;13(11):67.
   PubMed Web of Science ®Google Scholar
• Li D, Edwards RJ, Manne K, et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021;184(16):4203–4219 e32. doi:10.1016/j.cell.2021.06.021
   PubMed Web of Science ®Google Scholar
• Shimizu J, Sasaki T, Koketsu R, et al. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Sci Rep. 2022;12(1):15612. doi:10.1038/s41598-022-19993-w
   PubMed Web of Science ®Google Scholar
• Wang S, Wang J, Yu X, et al. Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcgammaRIIB and virus-antibody complex with bivalent interaction. Commun Biol. 2022;5(1):262. doi:10.1038/s42003-022-03207-0
   PubMed Web of Science ®Google Scholar
• Okuya K, Hattori T, Saito T, et al. Multiple Routes of Antibody-Dependent Enhancement of SARS-CoV-2 Infection. Microbiol Spectr. 2022;10(2):e0155321. doi:10.1128/spectrum.01553-21
   PubMed Web of Science ®Google Scholar
• Maemura T, Kuroda M, Armbrust T, Yamayoshi S, Halfmann PJ, Kawaoka Y. Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcgammaRIIA and FcgammaRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages. mBio. 2021;12(5):e0198721. doi:10.1128/mBio.01987-21
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20(6):339–341. doi:10.1038/s41577-020-0321-6
   PubMed Web of Science ®Google Scholar
• Lee WS, Wheatley AK, Kent SJ, DeKosky BJ. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185–1191. doi:10.1038/s41564-020-00789-5
   PubMed Web of Science ®Google Scholar
• Liu Y, Soh WT, Kishikawa JI, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021;184(13):3452–3466 e18. doi:10.1016/j.cell.2021.05.032
   PubMed Web of Science ®Google Scholar
• Shimizu J, Sasaki T, Yamanaka A, et al. The potential of COVID-19 patients’ sera to cause antibody-dependent enhancement of infection and IL-6 production. Sci Rep. 2021;11(1):23713. doi:10.1038/s41598-021-03273-0
   PubMed Web of Science ®Google Scholar
• Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584(7821):353–363. doi:10.1038/s41586-020-2538-8
   PubMed Web of Science ®Google Scholar
• Zang J, Gu C, Zhou B, et al. Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. Cell Discov. 2020;6:61. doi:10.1038/s41421-020-00199-1
   PubMed Web of Science ®Google Scholar
• Li JF, He L, Deng YQ, et al. Generation and Characterization of a Nanobody Against SARS-CoV. Virol Sin. 2021;36(6):1484–1491. doi:10.1007/s12250-021-00436-1
   PubMed Web of Science ®Google Scholar
• Hanke L, Vidakovics Perez L, Sheward DJ, et al. An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction. Nat Commun. 2020;11(1):4420. doi:10.1038/s41467-020-18174-5
   PubMed Web of Science ®Google Scholar
• Chi X, Zhang X, Pan S, et al. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants. Signal Transduct Target Ther. 2022;7(1):44. doi:10.1038/s41392-022-00912-4
   PubMed Web of Science ®Google Scholar
• Weinstein JB, Bates TA, Leier HC, McBride SK, Barklis E, Tafesse FG. A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants. iScience. 2022;25(3):103960. doi:10.1016/j.isci.2022.103960
   PubMed Web of Science ®Google Scholar
• Lu Q, Zhang Z, Li H, et al. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein. J Nanobiotechnology. 2021;19(1):33. doi:10.1186/s12951-021-00768-w
   PubMed Web of Science ®Google Scholar
• Xiang Y, Nambulli S, Xiao Z, et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science. 2020;370(6523):1479–1484. doi:10.1126/science.abe4747
   PubMed Web of Science ®Google Scholar
• Wagner TR, Schnepf D, Beer J, et al. Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern. EMBO Rep. 2022;23(2):e53865. doi:10.15252/embr.202153865
   PubMed Web of Science ®Google Scholar
• Yang Q, Jian X, Syed AAS, et al. Structural Comparison and Drug Screening of Spike Proteins of Ten SARS-CoV-2 Variants. Research. 2022;2022:9781758. doi:10.34133/2022/9781758
   PubMedGoogle Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–424. doi:10.1038/s41579-021-00573-0
   PubMed Web of Science ®Google Scholar
• Sungnak W, Huang N, Becavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687. doi:10.1038/s41591-020-0868-6
   PubMed Web of Science ®Google Scholar
• Zhou R, Wang P, Wong YC, et al. Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine. 2022;75:103762. doi:10.1016/j.ebiom.2021.103762
   PubMed Web of Science ®Google Scholar
• Froberg J, Gillard J, Philipsen R, et al. SARS-CoV-2 mucosal antibody development and persistence and their relation to viral load and COVID-19 symptoms. Nat Commun. 2021;12(1):5621. doi:10.1038/s41467-021-25949-x
   PubMed Web of Science ®Google Scholar
• Fan W, Sun S, Zhang N, et al. Nasal delivery of thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection. Signal Transduct Target Ther. 2022;7(1):55. doi:10.1038/s41392-022-00911-5
   PubMed Web of Science ®Google Scholar
• Halwe S, Kupke A, Vanshylla K, et al. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. Viruses. 2021;13(8):87.
   PubMed Web of Science ®Google Scholar
• Chen RE, Winkler ES, Case JB, et al. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. Nature. 2021;596(7870):103–108. doi:10.1038/s41586-021-03720-y
   PubMed Web of Science ®Google Scholar
• Nambulli S, Xiang Y, Tilston-Lunel NL, et al. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci Adv. 2021;7(22):45.
   Web of Science ®Google Scholar
• Li C, Zhan W, Yang Z, et al. Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell. 2022;185(8):1389–1401 e18. doi:10.1016/j.cell.2022.03.009
   PubMed Web of Science ®Google Scholar
• Esparza TJ, Chen Y, Martin NP, et al. Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19. MAbs. 2022;14(1):2047144. doi:10.1080/19420862.2022.2047144
   PubMed Web of Science ®Google Scholar